FiercePharmaAsia—Takeda's workforce rejig and Velcade patent win, China's insurance drug list | Fierce Pharma
Novartis loses in patent appeal over multiple sclerosis drug Gilenya | The Financial Express
Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS - Bloomberg
Novartis wins Supreme Court temporary reprieve on Gilenya generics (NYSE:NVS) | Seeking Alpha
natco: Patent infringement lawsuit filed against Natco by Johnson & Johnson, Momenta - The Economic Times
Alembic Pharma gets USFDA approval for hypertension drug - Elets eHealth
It's confirmed: Amarin loses Vascepa patent appeal, putting generics defense on life support | Fierce Pharma
HEC Pharm Awaits Fate As Novartis Petitions On US Gilenya Victory :: Generics Bulletin
Novartis could snag a blockbuster MS market all for itself, just in time to fight Gilenya generics | Fierce Pharma
Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study | Fierce Pharma
/cloudfront-us-east-2.images.arcpublishing.com/reuters/S2ZVV3DI4ZIZHAUZZLLFYCSR6Y.jpg "U.S. Supreme Court grants Novartis request to halt Gilenya generic rivals | Reuters")
U.S. Supreme Court grants Novartis request to halt Gilenya generic rivals | Reuters
Lilly fends off Cialis generics with new patent settlement | Fierce Pharma
Biogen takes another blow as appeal for Tecfidera patent revival falls short | Fierce Pharma
Novartis loses appeal for patent on multiple sclerosis drug (NYSE:NVS) | Seeking Alpha
/cloudfront-us-east-2.images.arcpublishing.com/reuters/UQPIK3T2DVOX7EIO4QZCM5HIAA.jpg "Novartis loses in patent appeal over multiple sclerosis drug | Reuters")
Novartis loses in patent appeal over multiple sclerosis drug | Reuters
Novartis' Gilenya staves off generic challengers—for now—after federal injunction | Fierce Pharma
Gilead's $3B Truvada will face generics a year early. Can Descovy still win over its patients? | Fierce Pharma
Biogen Suffers Yet Another Setback as an Appeal for the Tecfidera Patent is Denied. | News & Updates
Sole Challenger HEC Beaten On US Gilenya Patent :: Generics Bulletin
Novartis (NOVN) Wins U.S. Appeal Affirming Patent on MS Drug - Bloomberg
The top 10 generic drug makers by 2021 revenue
FDA greenlights generics of Novartis' $3B MS star Gilenya amid legal fight | Fierce Pharma
/cloudfront-us-east-2.images.arcpublishing.com/reuters/52AGE63A7FL7ZKCF7MWDNTV7QQ.jpg "U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug | Reuters")
U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug | Reuters
Alembic Pharma (Oral Solids ==> Injectables, Onco, Derma, Opthalmic) - Not-so-Hidden Gems - ValuePickr Forum
Novartis' Gilenya patent loss sets MS market up for battle with early generics | Fierce Pharma
Alembic Pharma: How to win the US: Alembic Pharma will have to crack the complex-products game - The Economic Times
